{"id":57938,"date":"2026-02-25T14:56:28","date_gmt":"2026-02-25T06:56:28","guid":{"rendered":"https:\/\/flcube.com\/?p=57938"},"modified":"2026-02-25T14:56:29","modified_gmt":"2026-02-25T06:56:29","slug":"astellas-and-vir-biotechnology-partner-on-1-7b-pro-xten-tce-deal-vir-5500-targets-psma-in-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57938","title":{"rendered":"Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal \u2013 VIR-5500 Targets PSMA in Prostate Cancer"},"content":{"rendered":"\n

Astellas Pharma Inc. (TYO:\u202f4503<\/a>)<\/strong> and Vir Biotechnology, Inc. (NASDAQ:\u202fVIR<\/a>)<\/strong> announced a global strategic collaboration<\/strong> to advance VIR-5500<\/strong>, an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE)<\/strong> targeting PSMA<\/strong> for prostate cancer<\/strong> treatment. The partnership aims to accelerate clinical development while strengthening Astellas’ oncology pipeline and prostate cancer leadership<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Partner 1<\/strong><\/td>Astellas Pharma Inc. (TYO:\u202f4503)<\/td><\/tr>
Partner 2<\/strong><\/td>Vir Biotechnology, Inc. (NASDAQ:\u202fVIR)<\/td><\/tr>
Licensed Asset<\/strong><\/td>VIR-5500 (PRO-XTEN dual-masked CD3 TCE targeting PSMA)<\/td><\/tr>
Indication<\/strong><\/td>Prostate cancer<\/td><\/tr>
Upfront & Near-Term<\/strong><\/td>USD\u202f335\u202fmillion<\/strong><\/td><\/tr>
\u2014 Cash Upfront<\/td>USD\u202f240\u202fmillion<\/td><\/tr>
\u2014 Equity Investment<\/td>USD\u202f75\u202fmillion (at 50% premium)<\/td><\/tr>
\u2014 Near-Term Milestone<\/td>USD\u202f20\u202fmillion<\/td><\/tr>
Development Cost Split<\/strong><\/td>Astellas 60% \/ Vir 40%<\/td><\/tr>
Milestone Potential<\/strong><\/td>Up to USD\u202f1.37\u202fbillion<\/strong> (development, regulatory, sales)<\/td><\/tr>
Royalties<\/strong><\/td>Tiered double-digit on ex-U.S. net sales<\/td><\/tr>
Total Potential Value<\/strong><\/td>>\u202fUSD\u202f1.7\u202fbillion<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercialization Structure<\/h2>\n\n\n\n
Phase<\/th>Responsibility<\/th><\/tr><\/thead>
Ongoing Phase 1<\/strong><\/td>Vir Biotechnology (until transition)<\/td><\/tr>
Post-Phase 1 Development<\/strong><\/td>Astellas (global lead)<\/td><\/tr>
U.S. Commercialization<\/strong><\/td>Vir option to co-promote; 50\/50 profit\/loss share<\/td><\/tr>
Ex-U.S. Commercialization<\/strong><\/td>Astellas exclusive<\/td><\/tr>
Global Development Costs<\/strong><\/td>Shared 60\/40 (Astellas\/Vir)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile \u2013 VIR-5500<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Platform<\/strong><\/td>PRO-XTEN dual-masked technology<\/td><\/tr>
Class<\/strong><\/td>CD3 T-cell engager (TCE)<\/td><\/tr>
Target<\/strong><\/td>PSMA (prostate-specific membrane antigen)<\/strong> \u2013 highly expressed on prostate cancer cells<\/td><\/tr>
Mechanism<\/strong><\/td>Redirects T-cells to kill PSMA-expressing tumor cells; dual-masking reduces off-tumor toxicity<\/td><\/tr>
Clinical Status<\/strong><\/td>Phase 1 ongoing<\/td><\/tr>
Differentiation<\/strong><\/td>PRO-XTEN masking technology potentially improves safety vs. unmasked TCEs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n